Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.
Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
Type:
Grant
Filed:
January 23, 2001
Date of Patent:
June 29, 2004
Assignee:
Pfizer Inc.
Inventors:
Wesley W. Day, Andrew G. Lee, David D. Thompson
Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.
Type:
Grant
Filed:
January 31, 2002
Date of Patent:
May 25, 2004
Assignee:
Nastech Pharmaceutical Company, Inc.
Inventors:
Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
Abstract: A composition for topical analgesic and antiseptic use which consists essentially of a approximately equal proportions of alcohol, turpentine, and eucalyptus oil.
Abstract: A method of treating tumors in a mammal, especially a human that have demonstrated resistance to oncology with taxane oncology agents is disclosed. The method is effective where the tumor has initially been unresponsive to taxane therapy or has developed resistance during the course of treatment. The method comprising the administration of an epothilone derivative selected from those represented by formula I:
The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that both are efficacious upon oral administration.
Abstract: A thickened film-forming composition comprising a film-forming polymer and, as thickener, a polysaccharide alkyl ether formed of units containing at least two different saccharide rings, each unit containing at least one hydroxyl group substituted with a saturated hydrocarbon-based alkyl chain. The polysaccharide alkyl ether preferably has a molecular weight of greater than 200,000 and is in particular a guar gum alkyl ether having a degree of substitution of from about 2 to 3, in particular 2.5. The composition can be used in particular in the cosmetics fields for keratinous materials, especially the nails.
Abstract: Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10−5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.
Abstract: The therapeutic combination comprises as its associated active ingredients calcium in elemental form and at least one vitamin D. It also contains at least one dry and moist binder combined in synergistic quantity with at least one diluant, at least one binder, and at least one lubricant, at least one of said diluant and said binder being a sweetening agent. Advantageously, the ratio of calcium in elemental form to vitamin D, expressed in mg of elemental Ca per IU of vitamin D lies in the range 1 to 1.5, and preferably in the range 1.2 to 1.3.
Abstract: A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I)
where
R1 is a group bound by a peptidic bond and selected from the group consisting of a hydrogen atom, a hydroxyl group, an acyl group, acyloxy group and a substituted or unsubstituted aminoacid;
R2 is a group bond by a peptidic bond and selected from the group consisting of a hydroxyl group, an amine group, an alkoxy group, an alkylamine group, a silyloxy group or a substituted or unsubstituted aminoacid; and n is 3 or 4.
Abstract: This invention relates to compositions and methods for achieving a therapeutic effect such as lowering blood pressure and treating congestive heart failure in a mammal. More specifically, this invention relates to synergistic compositions comprising amounts of at least two therapeutic agents selected from the group consisting of a renin inhibitor, an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist, which inhibitors and antagonists are present in amounts sufficient to cause synergistic therapeutic effects such as lowering blood pressure and treating congestive heart failure in a mammal.
Abstract: Methods of using compounds of formula (I):
their racemates, enantiomers, diastereoisomers and inorganic acid salts and organic acid salts thereof.
Type:
Grant
Filed:
July 25, 2002
Date of Patent:
March 30, 2004
Assignee:
Aventis Pharma S.A.
Inventors:
Jean-Claude Hardy, Jean Bouquerel, Patrick Nemecek, Jean-Claude Aloup, Serge Mignani, Jean-François Peyronel
Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.
Abstract: Disclosed are aerosol hair spray compositions which comprise a first and a second silicone-grafted copolymer, wherein the copolymers exhibit a dichotomous viscosity behavior which results in superior hold and excellent hair feel benefits, and a method of styling hair comprising applying to the hair an effective amount of the above composition. The aerosol hair spray compositions comprise: (A) from about 0.
Type:
Grant
Filed:
March 5, 1999
Date of Patent:
March 9, 2004
Assignee:
The Procter & Gamble Company
Inventors:
Jose Antonio Carballada, Thomas Allen Hutchins
Abstract: A composition for the treatment of skin consists essentially of a carboxylated, acidic amino acid obtained by acidifying an acidic amino acid with a carboxylic acid. The resultant material, which is also referred to as a tricarboxylic acid or an amino fruit acid, has significant benefit for the treatment of a number of skin conditions. In addition, the composition of the present invention is very noncaustic to skin, even when employed at a pH as low as 0.5. Also disclosed herein are therapeutic methods and compositions which employ the carboxylated acidic amino acids.
Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.